FDA approves gene-targeting cancer drug

The FDA's approval of selpercatinib marks a significant milestone in personalized cancer treatment, offering hope to patients with advanced cancers who have a rare genetic alteration. This drug, known as Retevmo, specifically targets the RET gene fusion, effectively halting cell growth and potentially improving outcomes for those who previously had limited treatment options. This move underscores the growing importance of precision medicine and could set a precedent for future gene-targeting therapies, offering a more tailored approach to cancer treatment.